BioLife Solutions Inc (NAS:BLFS)

Q3 2025 BioLife Solutions Inc Earnings Call Transcript

Nov 6, 2025 / 09:30 PM GMT

Release Date Price: $27.02 (-1.99%)

Transcript 10-Q8-K

Key Points

Positve

BioLife Solutions Inc (BLFS) reported a 33% year-over-year increase in cell processing revenue, contributing to a 31% increase in total revenue for the quarter.
The company raised its full-year 2025 revenue guidance, reflecting strong execution and momentum in recent quarters.
The sale of the Evo cold chain logistics product line for $25 million in cash has strengthened the company's balance sheet, bringing cash and marketable securities to approximately $125 million.
BioLife Solutions Inc (BLFS) achieved an adjusted EBITDA margin expansion of 500 basis points year over year to 28%, demonstrating improved profitability.
The company has a strong presence in the cell and gene therapy (CGT) landscape, with its biopreservation media embedded in 16 approved therapies and utilized in over 250 relevant clinical trials in the US.

Negative

The adjusted gross margin for the third quarter decreased to 64% from 67% in the prior year, primarily due to a $600,000 one-time inventory reserve.
GAAP operating expenses increased to $28.2 million from $21.8 million in the prior year, partly due to increased stock-based compensation expenses.
The company reported a GAAP operating loss of $89,000 for Q3 2025, although this was an improvement from the prior year.
There is a sequential decrease in revenue expected in Q4 compared to Q3 due to a $1.3 million media order shipped earlier than anticipated.
The company faces potential challenges in expanding its direct sales efforts, with a cautious approach to increasing headcount until a clear return on investment is evident.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BLFS.OQ - Biolife Solutions Inc
Q3 2025 BioLife Solutions Inc Earnings Call
Nov 06, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the Biolife Solutions 3rd quarter 2025 shareholder and analyst conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session.

Should you need assistance, please signal a conference specialist by pressing, then 0 on your telephone keypad.

I will now turn the call over to Troy Wicherman, Chief Financial Officer of Biolife Solutions. Please.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Go

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.